Cerecor licenses second CNS asset from Merck
This article was originally published in Scrip
Cerecor acquired worldwide, exclusive rights to develop and commercialize the Merck & Co compound MK-0657 (now CERC-301) – a small molecule NMDA receptor subunit 2 (NR2B) antagonist – in all indications, including depression. It is the first oral drug in the well-populated class of drugs targeting the NMDA receptor and the first oral rapid-acting antidepressant.
You may also be interested in...
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.